MyomoMYO -4.63%55 FCF Margin % is -26.61% as of Mar. 2026. GuruFocus rates MYO with a GF Score™ of 55/100 and a GF Value™ of $3.12 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Myomo ranks worse than 77.06% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Myomo's Free Cash Flow for the
three
months ended in Mar. 2026 was $-2.69 Mil. Myomo's Revenue for the
three
months ended in Mar. 2026 was $10.11 Mil. Therefore, Myomo's FCF Margin % for the quarter that ended in Mar. 2026 was -26.61%.
The historical rank and industry rank for Myomo's FCF Margin % or its related term are showing as below:
MYO'
s FCF Margin % Range Over the Past 10 Years
Min: -398.97 Med: -95.5 Max: -14.29
Current: -41.71
During the past 10 years, the highest FCF Margin % of Myomo was -14.29%. The lowest was -398.97%. And the median was -95.50%.
MYO's FCF Margin % is ranked worse than 77.06% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: -0.03
vs MYO: -41.71
Myomo FCF Margin % Related Terms
Myomo FCF Margin % Historical Data
* Premium members only.
The historical data trend for Myomo's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Myomo's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myomo FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Myomo's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Myomo's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myomo (MYO) has a FCF Margin % of -26.61% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Myomo and its competitors. According to the industry distribution chart, Myomo ranks #628 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 77.1%.
Is Myomo's FCF Margin % too high?
Myomo's current FCF Margin % is -26.61%. Based on the distribution chart, Myomo ranks #628 out of 815 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Myomo has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Myomo's FCF Margin % compare to NSYS and NSPR?
According to the Medical Devices & Instruments industry distribution chart, Myomo ranks #628 out of 815 companies for FCF Margin %. This places Myomo in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Myomo and its competitors. Myomo's current FCF Margin % is -26.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Myomo stock overvalued right now?
Based on GuruFocus' analysis, Myomo (MYO) is currently considered Possible Value Trap. The stock's GF Value™ is $3.12, compared to a current price of $1.03 — trading 67% below its estimated fair value. The current FCF Margin % is -26.61%. Myomo's overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Myomo (MYO), the current FCF Margin % is -26.61% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Myomo (MYO) Overvalued in 2026?
Based on GuruFocus' analysis, Myomo stock appears to be undervalued.
The current stock price of $1.03 is trading 67% below its estimated GF Value™ of $3.12.
GuruFocus considers Myomo to be Possible Value Trap.
Key valuation signals for MYO:
FCF Margin %: -26.61%
GF Value™: $3.12 vs. price of $1.03 (67% below fair value)
No single metric tells the full story. See the MYO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA). Geographically, it derives maximum revenue from the United States, followed by Germany, and other international.
55GF Score
Get the complete analysis for MYO
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MYO has been successfully added to your 
